Norverapamil (BioDeep_00000408993)

   


代谢物信息卡片


Norverapamil

化学式: C26H36N2O4 (440.2674936)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C(C(C(C)C)(c(c2)cc(c(OC)c2)OC)C#N)CCNCCc(c1)cc(OC)c(OC)c1
InChI: InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3

描述信息

D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers
D000077264 - Calcium-Regulating Hormones and Agents
D049990 - Membrane Transport Modulators

同义名列表

1 个代谢物同义名

Norverapamil



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Shuangjiao Sun, Yanfen Wei, Hao Wang, Lifu Tang, Biyang Deng. Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. Journal of chromatographic science. 2021 Feb; 59(3):289-296. doi: 10.1093/chromsci/bmaa098. [PMID: 33333557]
  • Hongping Yao, Changhe Wang, Wen Lu, Wen Li, Wanghui Jing, Jiye Zhang, Guangde Yang, Aiguo Zeng. Comparative pharmacokinetics of verapamil and norverapamil in normal and ulcerative colitis rats after oral administration of low and high dose verapamil by UPLC-MS/MS. Xenobiotica; the fate of foreign compounds in biological systems. 2020 Jun; 50(6):713-721. doi: 10.1080/00498254.2019.1682715. [PMID: 31633443]
  • Eleanor Jing Yi Cheong, Denise Wun Xi Teo, Denise Xin Yi Chua, Eric Chun Yong Chan. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban. Drug metabolism and disposition: the biological fate of chemicals. 2019 11; 47(11):1291-1306. doi: 10.1124/dmd.119.086918. [PMID: 31506301]
  • Zhongyu Li, Lei Jiang, Yujuan Zhu, Wentao Su, Cong Xu, Tingting Tao, Yang Shi, Jianhua Qin. Assessment of hepatic metabolism-dependent nephrotoxicity on an organs-on-a-chip microdevice. Toxicology in vitro : an international journal published in association with BIBRA. 2018 Feb; 46(?):1-8. doi: 10.1016/j.tiv.2017.10.005. [PMID: 28986290]
  • Juciane Lauren Cavalcanti Cardoso, Vera Lucia Lanchote, Maria Paula Marques Pereira, Jorge Manuel Vieira Capela, Natália Valadares de Moraes, José Salvador Lepera. Impact of inhalational exposure to ethanol fuel on the pharmacokinetics of verapamil, ibuprofen and fluoxetine as in vivo probe drugs for CYP3A, CYP2C and CYP2D in rats. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2015 Oct; 84(?):99-105. doi: 10.1016/j.fct.2015.08.002. [PMID: 26265240]
  • Janthima Methaneethorn, Munlikar Chamnansua, Natnaree Kaewdang, Manupat Lohitnavy. A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference. 2014; 2014(?):5711-4. doi: 10.1109/embc.2014.6944924. [PMID: 25571292]
  • Sibylle Neuhoff, Karen Rowland Yeo, Zoe Barter, Masoud Jamei, David B Turner, Amin Rostami-Hodjegan. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. Journal of pharmaceutical sciences. 2013 Sep; 102(9):3161-73. doi: 10.1002/jps.23607. [PMID: 23686764]
  • Matylda Resztak, Franciszek K Główka. Stereoselective CZE method for analysis of verapamil and norverapamil in human plasma. Acta poloniae pharmaceutica. 2013 May; 70(3):395-401. doi: NULL. [PMID: 23757929]
  • Puran Singhal, Manish Yadav, Serge Winter, Swati Guttikar, Dharmesh Patel, Malcolm Mills, Pranav S Shrivastav. Enantiomeric separation of verapamil and its active metabolite, norverapamil, and simultaneous quantification in human plasma by LC-ESI-MS-MS. Journal of chromatographic science. 2012 Oct; 50(9):839-48. doi: 10.1093/chromsci/bms080. [PMID: 22677487]
  • Young Sun Lee, Ji Na Yoon, In-Soo Yoon, Myung Gull Lee, Hee Eun Kang. Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407. Xenobiotica; the fate of foreign compounds in biological systems. 2012 Aug; 42(8):766-74. doi: 10.3109/00498254.2011.654001. [PMID: 22300394]
  • Nan Hu, Shanshan Xie, Li Liu, Xinting Wang, Xian Pan, Guanming Chen, Lulu Zhang, Haiyan Liu, Xiang Liu, Xiaodong Liu, Lin Xie, Guangji Wang. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug metabolism and disposition: the biological fate of chemicals. 2011 Mar; 39(3):419-25. doi: 10.1124/dmd.110.035642. [PMID: 21135265]
  • Sam Rebello, Selene Leon, Sam Hariry, Marion Dahlke, Venkateswar Jarugula. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants. Journal of clinical pharmacology. 2011 Feb; 51(2):218-28. doi: 10.1177/0091270010365717. [PMID: 20413453]
  • Shan-Shan Xie, Nan Hu, Xin-Yue Jing, Xiao-Dong Liu, Lin Xie, Guang-Ji Wang, Chang-Hui Liu. Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats. The Journal of pharmacy and pharmacology. 2010 Apr; 62(4):440-7. doi: 10.1211/jpp.62.04.0005. [PMID: 20604832]
  • Dong-Hyun Choi, Joong-Hwa Chung, Jun-Shik Choi. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. European journal of clinical pharmacology. 2010 Mar; 66(3):285-90. doi: 10.1007/s00228-009-0757-x. [PMID: 20012601]
  • Daniel R Mudra, Ronald T Borchardt. Absorption barriers in the rat intestinal mucosa. 3: Effects of polyethoxylated solubilizing agents on drug permeation and metabolism. Journal of pharmaceutical sciences. 2010 Feb; 99(2):1016-27. doi: 10.1002/jps.21836. [PMID: 19650119]
  • Daniel R Mudra, Ronald T Borchardt. Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism. Journal of pharmaceutical sciences. 2010 Feb; 99(2):982-98. doi: 10.1002/jps.21912. [PMID: 19746412]
  • Fabiano H Mateus, José S Lepera, Maria Paula Marques, Vanessa B Boralli, Vera L Lanchote. Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. Chirality. 2010 Jan; 22(1):29-34. doi: 10.1002/chir.20700. [PMID: 19229957]
  • Helena Anna Thörn, Mikael Hedeland, Ulf Bondesson, Lars Knutson, Mohammed Yasin, Paul Dickinson, Hans Lennernäs. Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: important for the mechanistic understanding of first-pass drug-drug interactions. Drug metabolism and disposition: the biological fate of chemicals. 2009 Nov; 37(11):2186-96. doi: 10.1124/dmd.109.028027. [PMID: 19687151]
  • Soon-Pyo Hong, Kyoung-Sig Chang, Young-Youp Koh, Dong-Hyun Choi, Jun-Shik Choi. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin. Archives of pharmacal research. 2009 Oct; 32(10):1447-52. doi: 10.1007/s12272-009-2015-2. [PMID: 19898809]
  • Dong-Hyun Choi, Cheng Li, Jun-Shik Choi. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. European journal of drug metabolism and pharmacokinetics. 2009 Jul; 34(3-4):163-8. doi: 10.1007/bf03191168. [PMID: 20166433]
  • Aernout D van Haarst, Anneke C Dijkmans, Hans-Josef Weimann, Michiel J B Kemme, Jacobus J Bosch, Rik C Schoemaker, Adam F Cohen, Jacobus Burggraaf. Clinically important interaction between tedisamil and verapamil. Journal of clinical pharmacology. 2009 May; 49(5):560-7. doi: 10.1177/0091270009332812. [PMID: 19299533]
  • Amy C Young, Larissa I Velez, Kurt C Kleinschmidt. Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose. Resuscitation. 2009 May; 80(5):591-3. doi: 10.1016/j.resuscitation.2009.01.023. [PMID: 19282085]
  • Jun Shik Choi, Jin Pil Burm. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. Archives of pharmacal research. 2008 Sep; 31(9):1200-4. doi: 10.1007/s12272-001-1289-z. [PMID: 18806964]
  • Dong-Hyun Choi, Wan-Gyun Shin, Jun-Shik Choi. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. European journal of clinical pharmacology. 2008 May; 64(5):445-9. doi: 10.1007/s00228-007-0447-5. [PMID: 18193210]
  • F H Mateus, J S Lepera, M P Marques, V B Boralli, V L Lanchote. Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. Canadian journal of physiology and pharmacology. 2008 May; 86(5):232-9. doi: 10.1139/y08-017. [PMID: 18432283]
  • Yong-Ji Piao, Jun-Shik Choi. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Archives of pharmacal research. 2008 Apr; 31(4):518-22. doi: 10.1007/s12272-001-1187-4. [PMID: 18449511]
  • W Pan, J Y Ryu, J H Shon, I S Song, K H Liu, Y E Sunwoo, W Kang, J G Shin. Dietary salt does not influence the disposition of verapamil enantiomers in relation to efflux transporter ABCB1 genetic polymorphism in healthy Korean subjects. Xenobiotica; the fate of foreign compounds in biological systems. 2008 Apr; 38(4):422-34. doi: 10.1080/00498250701832446. [PMID: 18340565]
  • S Hanafy, N J Dagenais, W F Dryden, F Jamali. Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers. British journal of pharmacology. 2008 Jan; 153(1):90-9. doi: 10.1038/sj.bjp.0707538. [PMID: 17965735]
  • Fabiano Henrique Mateus, José Salvador Lepera, Maria Paula Marques, Vanessa Bergamin Boralli, Vera Lucia Lanchote. Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2007 Dec; 45(5):762-8. doi: 10.1016/j.jpba.2007.09.021. [PMID: 17981422]
  • Shuijun Li, Gangyi Liu, Jingying Jia, Yun Liu, Cheng Pan, Chen Yu, Yongbao Cai, Jianying Ren. Simultaneous determination of ten antiarrhythic drugs and a metabolite in human plasma by liquid chromatography--tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Mar; 847(2):174-81. doi: 10.1016/j.jchromb.2006.10.013. [PMID: 17113839]
  • S Dadashzadeh, B Javadian, S Sadeghian. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharmaceutics & drug disposition. 2006 Oct; 27(7):329-34. doi: 10.1002/bdd.512. [PMID: 16892180]
  • Girum L Lemma, Zaiqi Wang, Mitchell A Hamman, Narjis A Zaheer, J Christopher Gorski, Stephen D Hall. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clinical pharmacology and therapeutics. 2006 Mar; 79(3):218-30. doi: 10.1016/j.clpt.2005.11.001. [PMID: 16513446]
  • Hyoung J Kim, Jun S Choi. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. Biopharmaceutics & drug disposition. 2005 Oct; 26(7):295-300. doi: 10.1002/bdd.459. [PMID: 16013069]
  • Jun Shik Choi, Jin Pil Burm. Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. Archives of pharmacal research. 2005 Apr; 28(4):483-7. doi: 10.1007/bf02977680. [PMID: 15918524]
  • Hossein Amini, Abolhassan Ahmadiani. Sensitive determination of clarithromycin in human plasma by high-performance liquid chromatography with spectrophotometric detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2005 Mar; 817(2):193-7. doi: 10.1016/j.jchromb.2004.12.003. [PMID: 15686985]
  • Jun-Shik Choi, Hyo-Kyug Han. The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits. The Journal of pharmacy and pharmacology. 2004 Dec; 56(12):1537-42. doi: 10.1211/0022357044814. [PMID: 15563760]
  • Mikael Hedeland, Elisabeth Fredriksson, Hans Lennernäs, Ulf Bondesson. Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 May; 804(2):303-11. doi: 10.1016/j.jchromb.2004.01.026. [PMID: 15081924]
  • Christer Tannergren, Helena Engman, Lars Knutson, Mikael Hedeland, Ulf Bondesson, Hans Lennernäs. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clinical pharmacology and therapeutics. 2004 Apr; 75(4):298-309. doi: 10.1016/j.clpt.2003.12.012. [PMID: 15060508]
  • A Tracqui, C Tournoud, P Kintz, M Villain, C Kummerlen, P Sauder, B Ludes. HPLC/MS findings in a fatality involving sustained-release verapamil. Human & experimental toxicology. 2003 Sep; 22(9):515-21. doi: 10.1191/0960327103ht389oa. [PMID: 14580012]
  • Cindy Woodland, Gideon Koren, Irving W Wainer, Gerry Batist, Shinya Ito. Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. Canadian journal of physiology and pharmacology. 2003 Aug; 81(8):800-5. doi: 10.1139/y03-073. [PMID: 12897809]
  • J Borlak, M Walles, M Elend, T Thum, A Preiss, K Levsen. Verapamil: identification of novel metabolites in cultures of primary human hepatocytes and human urine by LC-MS(n) and LC-NMR. Xenobiotica; the fate of foreign compounds in biological systems. 2003 Jun; 33(6):655-76. doi: 10.1080/0049825031000093600. [PMID: 12851041]
  • Jean-Marie Dethy, Bradley L Ackermann, Claude Delatour, Jack D Henion, Gary A Schultz. Demonstration of direct bioanalysis of drugs in plasma using nanoelectrospray infusion from a silicon chip coupled with tandem mass spectrometry. Analytical chemistry. 2003 Feb; 75(4):805-11. doi: 10.1021/ac0260692. [PMID: 12622370]
  • M Walles, W M Mullett, K Levsen, J Borlak, G Wünsch, J Pawliszyn. Verapamil drug metabolism studies by automated in-tube solid phase microextraction. Journal of pharmaceutical and biomedical analysis. 2002 Sep; 30(2):307-19. doi: 10.1016/s0731-7085(02)00267-4. [PMID: 12191717]
  • Rajinder K Bhardwaj, Hartmut Glaeser, Laurent Becquemont, Ulrich Klotz, Suresh K Gupta, Martin F Fromm. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. The Journal of pharmacology and experimental therapeutics. 2002 Aug; 302(2):645-50. doi: 10.1124/jpet.102.034728. [PMID: 12130727]
  • Wiesław Sawicki, Stanisław Janicki. Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation. International journal of pharmaceutics. 2002 May; 238(1-2):181-9. doi: 10.1016/s0378-5173(02)00069-8. [PMID: 11996822]
  • Uwe Fuhr, Herbert Müller-Peltzer, Rainer Kern, Pablo Lopez-Rojas, Manfred Jünemann, Sebastian Harder, A Horst Staib. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. European journal of clinical pharmacology. 2002 Apr; 58(1):45-53. doi: 10.1007/s00228-002-0436-7. [PMID: 11956673]
  • Wieslaw Sawicki. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2002 Jan; 53(1):29-35. doi: 10.1016/s0939-6411(01)00189-8. [PMID: 11777750]
  • Y Mori, K Hanada, T Mori, Y Tsukahara, M Hashiguchi, H Ogata. Stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil in rabbits. Biological & pharmaceutical bulletin. 2001 Jul; 24(7):806-10. doi: 10.1248/bpb.24.806. [PMID: 11456122]
  • E Brandsteterová, G Endresz, G Blaschke. Chiral separation of verapamil and some of its metabolites by HPLC and CE. Die Pharmazie. 2001 Jul; 56(7):536-41. doi: NULL. [PMID: 11487971]
  • W Sawicki. A validated method for the determination of verapamil and norverapamil in human plasma. Journal of pharmaceutical and biomedical analysis. 2001 Jun; 25(3-4):689-95. doi: 10.1016/s0731-7085(00)00585-9. [PMID: 11377051]
  • C Solans, M A Bregante, J J Aramayona, L J Fraile, M A Garcia. Pharmacokinetics of verapamil in New Zealand white rabbits during ontogeny. Biology of the neonate. 2000 Nov; 78(4):321-6. doi: 10.1159/000014287. [PMID: 11093014]
  • C Pauli-Magnus, O von Richter, O Burk, A Ziegler, T Mettang, M Eichelbaum, M F Fromm. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. The Journal of pharmacology and experimental therapeutics. 2000 May; 293(2):376-82. doi: . [PMID: 10773005]
  • M E Krecic-Shepard, C R Barnas, J Slimko, J C Gorski, I W Wainer, J B Schwartz. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clinical pharmacology and therapeutics. 1999 Jul; 66(1):40-50. doi: 10.1016/s0009-9236(99)70052-4. [PMID: 10430108]
  • M De Cicco, F Macor, I Robieux, G Zanette, D Fantin, F Fabiani, G Nicolosi, A Fracasso, G Toffoli, C Santantonio, C Lestuzzi, M Matovic, M Boiocchi. Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit. Critical care medicine. 1999 Feb; 27(2):332-9. doi: 10.1097/00003246-199902000-00040. [PMID: 10075058]
  • J Rui, X Zhou, S Lin, Y Yuan, B Xiang, D An. [Simultaneous determination of the enantiomers of verapamil and norverapamil in plasma by high performance capillary electrophoresis]. Yao xue xue bao = Acta pharmaceutica Sinica. 1998 Jul; 33(7):517-22. doi: NULL. [PMID: 12016885]
  • E B Asafu-Adjaye, G K Shiu. Solid-phase extraction-high-performance liquid chromatography determination of verapamil and norverapamil enantiomers in urine. Journal of chromatography. B, Biomedical sciences and applications. 1998 Apr; 707(1-2):161-7. doi: 10.1016/s0378-4347(97)00575-6. [PMID: 9613945]
  • S W Siegner, R L Giovanoni, K A Erickson, P A Netland. Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 1998 Apr; 14(2):159-68. doi: 10.1089/jop.1998.14.159. [PMID: 9572542]
  • K T Kivistö, P J Neuvonen, L Tarssanen. Pharmacokinetics of verapamil in overdose. Human & experimental toxicology. 1997 Jan; 16(1):35-7. doi: 10.1177/0960327197016001071. [PMID: 9023574]
  • A Ceccato, P Chiap, P Hubert, B Toussaint, J Crommen. Automated determination of verapamil and norverapamil in human plasma with on-line coupling of dialysis to high-performance liquid chromatography and fluorometric detection. Journal of chromatography. A. 1996 Oct; 750(1-2):351-60. doi: 10.1016/0021-9673(96)00471-2. [PMID: 8938391]
  • M A Robinson, R Mehvar. Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding. Biopharmaceutics & drug disposition. 1996 Oct; 17(7):577-87. doi: 10.1002/(sici)1099-081x(199610)17:7<577::aid-bdd984>3.0.co;2-p. [PMID: 8894116]
  • S K Gupta, B M Yih, L Atkinson, J Longstreth. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil. Journal of clinical pharmacology. 1995 Nov; 35(11):1083-93. doi: 10.1002/j.1552-4604.1995.tb04031.x. [PMID: 8626882]
  • M M Bhatti, R Z Lewanczuk, F M Pasutto, R T Foster. Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity. Journal of clinical pharmacology. 1995 Nov; 35(11):1076-82. doi: 10.1002/j.1552-4604.1995.tb04030.x. [PMID: 8626881]
  • S K Gupta, L Atkinson, T Tu, J A Longstreth. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. British journal of clinical pharmacology. 1995 Oct; 40(4):325-31. doi: 10.1111/j.1365-2125.1995.tb04554.x. [PMID: 8554934]
  • R J Motzer, P Lyn, P Fischer, P Lianes, R L Ngo, C Cordon-Cardo, J P O'Brien. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Aug; 13(8):1958-65. doi: 10.1200/jco.1995.13.8.1958. [PMID: 7636536]
  • W H Wilson, C Jamis-Dow, G Bryant, F M Balis, R W Klecker, S E Bates, B A Chabner, S M Steinberg, D R Kohler, R E Wittes. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Aug; 13(8):1985-94. doi: 10.1200/jco.1995.13.8.1985. [PMID: 7636539]
  • R Mehvar, J Reynolds. Input rate-dependent stereoselective pharmacokinetics. Experimental evidence in verapamil-infused isolated rat livers. Drug metabolism and disposition: the biological fate of chemicals. 1995 Jun; 23(6):637-41. doi: NULL. [PMID: 7587945]
  • G Stagni, W R Gillespie. Simultaneous analysis of verapamil and norverapamil enantiomers in human plasma by high-performance liquid chromatography. Journal of chromatography. B, Biomedical applications. 1995 May; 667(2):349-54. doi: 10.1016/0378-4347(95)00019-f. [PMID: 7663711]
  • J A Johnson, W S Akers. Influence of metabolites on protein binding of verapamil enantiomers. British journal of clinical pharmacology. 1995 May; 39(5):536-8. doi: 10.1111/j.1365-2125.1995.tb04492.x. [PMID: 7669491]
  • D Piovan, R Padrini, G Svalato Moreolo, G Magnolfi, O Milanesi, R Zordan, P A Pellegrino, M Ferrari. Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment. Therapeutic drug monitoring. 1995 Feb; 17(1):60-7. doi: 10.1097/00007691-199502000-00010. [PMID: 7725379]
  • J Vlcek, K Macek, P Hůlek, M Brátová, Z Fendrich. Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy. Arzneimittel-Forschung. 1995 Feb; 45(2):146-9. doi: NULL. [PMID: 7710436]
  • L Tan, S R Yang, X Q Liu, Y S Yuan. [Simultaneous determination of verapamil and its major metabolite in human plasma by high performance liquid chromatography]. Yao xue xue bao = Acta pharmaceutica Sinica. 1995; 30(9):689-93. doi: NULL. [PMID: 8701745]
  • R Mehvar, J M Reynolds, M A Robinson, J A Longstreth. Enantioselective kinetics of verapamil and norverapamil in isolated perfused rat livers. Pharmaceutical research. 1994 Dec; 11(12):1815-9. doi: 10.1023/a:1018935921473. [PMID: 7899248]
  • S Fort, M J Lewis, D K Luscombe, D N John. Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter. British journal of clinical pharmacology. 1994 May; 37(5):460-3. doi: 10.1111/j.1365-2125.1994.tb05715.x. [PMID: 8054253]
  • J M Dethy, S De Broux, M Lesne, J Longstreth, P Gilbert. Stereoselective determination of verapamil and norverapamil by capillary electrophoresis. Journal of chromatography. B, Biomedical applications. 1994 Mar; 654(1):121-7. doi: 10.1016/0378-4347(93)e0455-y. [PMID: 8004233]
  • B B Lonsberry, M P Czubryt, D F Dubo, J S Gilchrist, J C Docherty, T G Maddaford, G N Pierce. Effect of chronic administration of verapamil on Ca++ channel density in rat tissue. The Journal of pharmacology and experimental therapeutics. 1992 Nov; 263(2):540-5. doi: NULL. [PMID: 1331402]
  • P H Hubert, P Chiap, A Ceccato, I Bechet, R Sibenaler-Dechamps, P Maes, J Crommen. Determination of verapamil and norverapamil in human plasma by liquid chromatography: comparison between a liquid-liquid extraction procedure and an automated liquid-solid extraction method for sample preparation. Journal of pharmaceutical and biomedical analysis. 1992 Oct; 10(10-12):937-42. doi: 10.1016/0731-7085(91)80102-f. [PMID: 1298400]
  • R Kern, E Brode, D Schöbel. Internally standardized simultaneous assay of verapamil and N-demethyl-verapamil enantiomers in human plasma by means of high performance liquid chromatography. Methods and findings in experimental and clinical pharmacology. 1992 Oct; 14(8):637-44. doi: NULL. [PMID: 1494303]
  • H Fieger, G Blaschke. Direct determination of the enantiomeric ratio of verapamil, its major metabolite norverapamil and gallopamil in plasma by chiral high-performance liquid chromatography. Journal of chromatography. 1992 Mar; 575(2):255-60. doi: 10.1016/0378-4347(92)80153-h. [PMID: 1629301]
  • M J Czejka, N Zwoelfer, B Podesser. Red blood cell partitioning of gallopamil, verapamil and norverapamil. Farmaco (Societa chimica italiana : 1989). 1992 Mar; 47(3):387-91. doi: NULL. [PMID: 1503601]
  • A Shibukawa, I W Wainer. Simultaneous direct determination of the enantiomers of verapamil and norverapamil in plasma using a derivatized amylose high-performance liquid chromatographic chiral stationary phase. Journal of chromatography. 1992 Feb; 574(1):85-92. doi: 10.1016/0378-4347(92)80101-u. [PMID: 1629292]
  • D Piovan, R Padrini, G Svaluto Moreolo, P A Pellegrino, M Ferrari. Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment. Pharmacological research. 1992 Feb; 25 Suppl 1(?):81-2. doi: 10.1016/1043-6618(92)90550-u. [PMID: 1508820]
  • J H Ahmed, P A Meredith, H L Elliott. The influence of age on the pharmacokinetics of verapamil. Pharmacological research. 1991 Oct; 24(3):227-33. doi: 10.1016/1043-6618(91)90085-c. [PMID: 1956867]
  • C Köppel, A Wagemann. Plasma level monitoring of D,L-verapamil and three of its metabolites by reversed-phase high-performance liquid chromatography. Journal of chromatography. 1991 Sep; 570(1):229-34. doi: 10.1016/0378-4347(91)80221-w. [PMID: 1797832]
  • P K Zachariah, T P Moyer, H M Theobald, R P Frantz, S B Kurtz, J T McCarthy, R L Smith. The pharmacokinetics of racemic verapamil in patients with impaired renal function. Journal of clinical pharmacology. 1991 Jan; 31(1):45-53. doi: 10.1002/j.1552-4604.1991.tb01885.x. [PMID: 2045528]
  • A I Kobzar', N G Menzianova, I I Ermakovich. [A chromatographic method of determining verapamil and norverapamil in blood plasma]. Laboratornoe delo. 1991; ?(4):73-4. doi: NULL. [PMID: 1715443]
  • S Mulligan, J Devane, M Martin. Dose proportionality of pharmacokinetics with a cr-verapamil formulation. European journal of drug metabolism and pharmacokinetics. 1991; Spec No 3(?):304-11. doi: NULL. [PMID: 1820898]
  • V Canonico, D Bonaduce, L De Caprio, A Nicolino, L Forgione, M Petretta, F Rengo. [The effects of slow-release verapamil in relation to plasma concentration in aged hypertensives. A study with continuous monitoring of arterial pressure and electrocardiogram]. Giornale italiano di cardiologia. 1990 Oct; 20(10):924-32. doi: NULL. [PMID: 2090531]
  • D Husum, A Johnsen, G Jensen. Requirements for drug monitoring of verapamil: experience from an unselected group of patients with cardiovascular disease. Pharmacology & toxicology. 1990 Mar; 66(3):163-9. doi: 10.1111/j.1600-0773.1990.tb00726.x. [PMID: 2333271]
  • Y Q Chu, I W Wainer. Determination of the enantiomers of verapamil and norverapamil in serum using coupled achiral-chiral high-performance liquid chromatography. Journal of chromatography. 1989 Dec; 497(?):191-200. doi: 10.1016/0378-4347(89)80018-0. [PMID: 2625456]
  • M A Eldon, M M Battle, R E Voigtman, W A Colburn. Differences in oral verapamil absorption as a function of time of day. Journal of clinical pharmacology. 1989 Nov; 29(11):989-93. doi: 10.1002/j.1552-4604.1989.tb03266.x. [PMID: 2600194]
  • S G Carruthers, D J Freeman, D G Bailey. Synergistic adverse hemodynamic interaction between oral verapamil and propranolol. Clinical pharmacology and therapeutics. 1989 Oct; 46(4):469-77. doi: 10.1038/clpt.1989.167. [PMID: 2791449]
  • T A Moreland, M E McMurdo, J McEwen. Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets. Biopharmaceutics & drug disposition. 1989 May; 10(3):311-9. doi: 10.1002/bdd.2510100309. [PMID: 2720134]
  • Z B Salama, C Dilger, W Czogalla, R Otto, H Jaeger. Quantitative determination of verapamil and metabolites in human serum by high-performance liquid chromatography and its application to biopharmaceutic investigations. Arzneimittel-Forschung. 1989 Feb; 39(2):210-5. doi: NULL. [PMID: 2730689]
  • C M Jespersen, N A Klitgaard, H Nielsen, J F Hansen. Sustained-release and instant-release verapamil in treatment of angina pectoris. European journal of clinical pharmacology. 1989; 36(6):625-7. doi: 10.1007/bf00637748. [PMID: 2776821]
  • P A Hynning, P Anderson, U Bondesson, L O Boréus. Liquid-chromatographic quantification compared with gas-chromatographic-mass-spectrometric determination of verapamil and norverapamil in plasma. Clinical chemistry. 1988 Dec; 34(12):2502-3. doi: 10.1093/clinchem/34.12.2502. [PMID: 3197291]
  • P K Narang, C L Blumhardt, A R Doran, D Pickar. Steady-state cerebrospinal fluid transfer of verapamil and metabolites in patients with schizophrenia. Clinical pharmacology and therapeutics. 1988 Nov; 44(5):550-7. doi: 10.1038/clpt.1988.193. [PMID: 3180637]
  • J J Hanyok, M S Chow, J Kluger, M W Izard. An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients. Journal of clinical pharmacology. 1988 Sep; 28(9):831-6. doi: 10.1002/j.1552-4604.1988.tb03224.x. [PMID: 3230150]
  • N P Jørgensen, R A Walstad. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations. Pharmacology & toxicology. 1988 Aug; 63(2):105-7. doi: 10.1111/j.1600-0773.1988.tb00919.x. [PMID: 3186615]
  • J C McCourty, J H Silas, G T Tucker, M S Lennard. The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. British journal of clinical pharmacology. 1988 Mar; 25(3):349-57. doi: 10.1111/j.1365-2125.1988.tb03313.x. [PMID: 3358897]